/ /

  • linkedin
  • Increase Font
  • Sharebar

    Predictors for the number of AMD injections

    Orlando—Retinal angiomatous proliferation (RAP) lesions, treatment with ranibizumab, the absence of subretinal fluid, and the absence of subretinal pigment epithelium fluid (RPE) were associated with fewer injections for neovascular age-related macular degeneration (AMD) among participants from the Comparison of AMD Treatments Trials (CATT), said Daniel F. Martin, MD.

    Dr. Martin, of the Cole Eye Institute, Cleveland Clinic, presented these results during a session on choroidal neovascularization (CNV) management at the 2014 meeting of the Association for Research in Vision and Ophthalmology.

    The individuals studied had neovascular AMD and were randomly assigned to receive injections of ranibizumab or bevacizumab for 2 years as needed (PRN). Participants were scheduled for evaluation every 4 weeks. If the ophthalmologist observed fluid on optical coherence tomography (OCT) or had other signs of neovascular activity, the patient received an injection.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results